Alexander C Egbe1, Yogesh N V Reddy1, Arooj R Khan1, Mohamad Al-Otaibi1, Emmanuel Akintoye2, Masaru Obokata1, Barry A Borlaug3. 1. The Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN 55906, United States. 2. Department of Internal Medicine, Wayne State University/Detroit Medical Center, Detroit, MI, United States. 3. The Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN 55906, United States. Electronic address: borlaug.barry@mayo.edu.
Abstract
BACKGROUND: Elevation in central venous pressure (CVP) plays a fundamental pathophysiologic role in Fontan circulation. Because there is no sub-pulmonary ventricle in this system, CVP also provides the driving force for pulmonary blood flow. We hypothesized that this would make Fontan patients more susceptible to even low-level elevation in pulmonary vascular resistance index (PVRI), resulting in greater systemic venous congestion and adverse outcomes. METHODS: Adult Fontan patients and controls without congenital heart disease undergoing clinical evaluation that included cardiac catheterization and echocardiography were examined retrospectively. Outcomes including all-cause mortality and the development of Fontan associated diseases (FAD, defined as protein losing enteropathy, cirrhosis, heart failure hospitalization, arrhythmia, or thromboembolism) were assessed from longitudinal assessment. RESULTS: As compared to controls (n = 82), Fontan patients (n = 164) were younger (36 vs 45 years, p < 0.001), more likely to be on anticoagulation or antiplatelet therapy, and more likely to have atrial arrhythmia or cirrhosis. There was a strong correlation between CVP and PVRI in the Fontan group (r = 0.79, p < 0.001), but there was no such relationship in controls. Elevated PVRI identified patients at increased risk for FAD (HR 1.92, 95% CI 1.39-2.41, p = 0.01), and composite endpoint of FAD and/or death (HR 1.89, 95% CI 1.32-2.53, p = 0.01) per 1 WU∗m2 increment. CONCLUSIONS: Systemic venous congestion, which is the primary factor in the pathogenesis of FAD and death, is related to even low-level abnormalities in pulmonary vascular function. Multicenter studies are needed to determine whether interventions targeting pulmonary vascular structure and function can improve outcomes in the Fontan population.
BACKGROUND: Elevation in central venous pressure (CVP) plays a fundamental pathophysiologic role in Fontan circulation. Because there is no sub-pulmonary ventricle in this system, CVP also provides the driving force for pulmonary blood flow. We hypothesized that this would make Fontan patients more susceptible to even low-level elevation in pulmonary vascular resistance index (PVRI), resulting in greater systemic venous congestion and adverse outcomes. METHODS: Adult Fontan patients and controls without congenital heart disease undergoing clinical evaluation that included cardiac catheterization and echocardiography were examined retrospectively. Outcomes including all-cause mortality and the development of Fontan associated diseases (FAD, defined as protein losing enteropathy, cirrhosis, heart failure hospitalization, arrhythmia, or thromboembolism) were assessed from longitudinal assessment. RESULTS: As compared to controls (n = 82), Fontan patients (n = 164) were younger (36 vs 45 years, p < 0.001), more likely to be on anticoagulation or antiplatelet therapy, and more likely to have atrial arrhythmia or cirrhosis. There was a strong correlation between CVP and PVRI in the Fontan group (r = 0.79, p < 0.001), but there was no such relationship in controls. Elevated PVRI identified patients at increased risk for FAD (HR 1.92, 95% CI 1.39-2.41, p = 0.01), and composite endpoint of FAD and/or death (HR 1.89, 95% CI 1.32-2.53, p = 0.01) per 1 WU∗m2 increment. CONCLUSIONS:Systemic venous congestion, which is the primary factor in the pathogenesis of FAD and death, is related to even low-level abnormalities in pulmonary vascular function. Multicenter studies are needed to determine whether interventions targeting pulmonary vascular structure and function can improve outcomes in the Fontan population.
Authors: Y Zongtao; W Huishan; W Zengwei; Z Hongyu; F Minhua; Li Xinmin; Z Nanbin; H Hongguang Journal: Thorac Cardiovasc Surg Date: 2010-11-25 Impact factor: 1.827
Authors: Camden L Hebson; Nancy M McCabe; Robert W Elder; William T Mahle; Michael McConnell; Brian E Kogon; Emir Veledar; Maan Jokhadar; Robert N Vincent; Anurag Sahu; Wendy M Book Journal: Am J Cardiol Date: 2013-09-25 Impact factor: 2.778
Authors: Alexander C Egbe; Heidi M Connolly; Christopher J McLeod; Naser M Ammash; Talha Niaz; Vidhushei Yogeswaran; Joseph T Poterucha; Muhammad Y Qureshi; David J Driscoll Journal: J Am Coll Cardiol Date: 2016-09-20 Impact factor: 24.094
Authors: Anders Hebert; Ulla R Mikkelsen; Ulf Thilen; Lars Idorn; Annette S Jensen; Edit Nagy; Katarina Hanseus; Keld E Sørensen; Lars Søndergaard Journal: Circulation Date: 2014-10-20 Impact factor: 29.690
Authors: Tarek Alsaied; Jouke P Bokma; Mark E Engel; Joey M Kuijpers; Samuel P Hanke; Liesl Zuhlke; Bin Zhang; Gruschen R Veldtman Journal: Heart Date: 2016-11-09 Impact factor: 5.994
Authors: Makoto Mori; Camden Hebson; Kayoko Shioda; Robert W Elder; Brian E Kogon; Fred H Rodriguez; Maan Jokhadar; Wendy M Book Journal: Congenit Heart Dis Date: 2016-03-02 Impact factor: 2.007
Authors: Jack Rychik; Gruschen Veldtman; Elizabeth Rand; Pierre Russo; Jonathan J Rome; Karen Krok; David J Goldberg; Anne Marie Cahill; Rebecca G Wells Journal: Pediatr Cardiol Date: 2012-04-26 Impact factor: 1.655
Authors: C G Stevens; J Kay; K Pickett; K Campbell; A D Khanna; E Yeung; S D Miyamoto; R M Jacobsen Journal: Pediatr Cardiol Date: 2021-06-18 Impact factor: 1.655
Authors: Peter Kramer; Anastasia Schleiger; Marie Schafstedde; Friederike Danne; Johannes Nordmeyer; Felix Berger; Stanislav Ovroutski Journal: Front Cardiovasc Med Date: 2022-03-10
Authors: Anastasia Schleiger; Peter Kramer; Hannes Sallmon; Niklas Jentsch; Marta Pileckaite; Friederike Danne; Marie Schafstedde; Hans-Peter Müller; Tobias Müller; Frank Tacke; Maximilian Jara; Martin Stockmann; Felix Berger; Stanislav Ovroutski Journal: Front Cardiovasc Med Date: 2022-09-07